This expert opinion is intended to support national decision-making by summarising the considerations and concerns of some EU/EEA countries when they discussed whether to introduce the 4CMenB vaccine into their national immunisation programmes.
This document updates the 2009 ECDC guidance on chlamydia control in Europe. The aim of this guidance is to support Member States to develop, implement or improve strategies for chlamydia control.
This guidance, based on a systematic review of the literature and expert opinion, suggests that there is good evidence to ensure that some key components are considered for inclusion in national and sub-national public health programmes in countries in Europe.
This evidence-based guidance is designed to inform the development, monitoring and evaluation of national strategies and programmes in countries in Europe in order to reduce and prevent infections among people who inject drugs.
The content of this joint guidance was developed by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) with the support of a technical advisory group composed of policy makers, service providers, civil society representatives and preventative health experts from throughout the EU/EEA.
The purpose of this document is to provide evidence-based guidance for good practice in public health management of sporadic cases of meningococcal disease and their contacts.
In June 2009, ECDC convened a technical expert consultation that focused on tuberculosis, new emerging airborne diseases (e.g. SARS) and meningococcal infections. This consultation was the second of a two-part process intended to assist national authorities in the EU Member States in the assessment of risks associated with the transmission of various infectious agents on board airplanes.
This document outlines the steps necessary to implement a comprehensive and effective control programme. It also offers advice on how to monitor and evaluate such programmes in order to ensure their effectiveness.
In the closed cabin environment of modern airplanes, passengers are frequently exposed to various infectious diseases. This report looks at 12 infectious diseases and, by systematically evaluating literature on on-board transmission, attempts to assess the risk of infection via air circulation in airplanes.
These guidelines are complemented by operational guidelines in relation to tuberculosis, new emerging airborne diseases (e.g. SARS) and meningococcal infections.